Maternal smoking and changes in drug metabolising enzymes in the human fetus

A. Zafeiri* (Corresponding Author), P. Filis, U. Soffientini, B. Lucendo-Villarin, A. Douglas, S. Shaw, J. P. Iredale, M. J. Swortwood, M. A. Huestis, M. Bellingham, R. T. Mitchell, D. C. Hays, P. J. O'Shaughnessy, P. A. Fowler

*Corresponding author for this work

Research output: Contribution to journalAbstractpeer-review


The placental feto-maternal interface allows for most drugs to freely diffuse and reach the developing fetus. Major phase I and II metabolising enzymes are expressed in the human fetal liver which is the primary site for metabolism of drug compounds. Maternal smoking passes ∼7,000 toxicants to the fetus, and is associated with multiple adverse consequences for peri/post-natal health and wellbeing in the offspring. Disruption of the drug metabolising machinery in the fetal liver also poses risks for drug toxicity. This study analysed drug metabolising enzymes (DME) expression levels in smoke-exposed human fetuses.
Original languageEnglish
Article numberP06-28
Pages (from-to)S114
Number of pages1
JournalToxicology Letters
Issue numberSupplement 1
Early online date12 Sept 2018
Publication statusPublished - 10 Oct 2018
Event54th Congress of the European-Societies-of-Toxicology (EUROTOX) - Toxicology Out of the Box - Brussels, Belgium
Duration: 2 Sept 20185 Sept 2018


Dive into the research topics of 'Maternal smoking and changes in drug metabolising enzymes in the human fetus'. Together they form a unique fingerprint.

Cite this